<doc>
  <docmeta id="113s214is">
    <bill congress="113" type="s" number="214" version="is"/>
    <revision size="23756" annotations="0" id="24" commit-time="2013-04-17T23:50:43+00:00" committer="favila" doc="113s214is/24.xml" status="complete">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" public-private="public">
	<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 214</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20130204">February 4, 2013</action-date>
			<action-desc>
        <sponsor name-id="S311">Ms. Klobuchar</sponsor> (for
			 herself, <cosponsor name-id="S153">Mr. Grassley</cosponsor>,
			 <cosponsor name-id="S253">Mr. Durbin</cosponsor>, <cosponsor name-id="S332">Mr.
			 Franken</cosponsor>, and <cosponsor name-id="S257">Mr. Johnson of South
			 Dakota</cosponsor>) introduced the following bill; which was read twice and
			 referred to the <committee-name committee-id="SSJU00">Committee on the
			 Judiciary</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To prohibit brand name drug companies from compensating
		  generic drug companies to delay the entry of a generic drug into the
		  market.</official-title>
	</form>
	<legis-body display-enacting-clause="no-display-enacting-clause">
		<section id="id86EDC939866A4BB6A73AF0BDA5BD2C43" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Preserve Access to Affordable Generics
			 Act</short-title>
        </quote>.</text>
		</section>
    <section id="id63E9BBDDC1E5451AA88A29CF8F9976F1">
      <enum>2.</enum>
      <header>Congressional
			 findings and declaration of purposes</header>
			<subsection id="id359904593A414EED94638B9697056156">
        <enum>(a)</enum>
        <header>Findings</header>
        <text>Congress
			 finds the following:</text>
				<paragraph id="idD1DDDFFF0CF74BADA11CF9634DB54D68">
          <enum>(1)</enum>
          <text>In 1984, the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Drug Price Competition and Patent Term Restoration Act">Drug
			 Price Competition and Patent Term Restoration Act</cato:entity-ref> (<cato:entity-ref entity-type="public-law" value="public-law/98/417">Public Law 98–417</cato:entity-ref>)</cato:entity> (referred
			 to in this Act as the <quote>1984 Act</quote>), was enacted with the intent of
			 facilitating the early entry of generic drugs while preserving incentives for
			 innovation.</text>
				</paragraph>
        <paragraph id="idFC5C9DD3119D49FFB1916854D168B496">
          <enum>(2)</enum>
          <text>Prescription
			 drugs make up 10 percent of the national health care spending but for the past
			 decade have been one of the fastest growing segments of health care
			 expenditures.</text>
				</paragraph>
        <paragraph id="idDE13742929BD4A8E973F8CD82719B413">
          <enum>(3)</enum>
          <text>Until recently,
			 the 1984 Act was successful in facilitating generic competition to the benefit
			 of consumers and health care payers—although 67 percent of all prescriptions
			 dispensed in the United States are generic drugs, they account for only 20
			 percent of all expenditures.</text>
				</paragraph>
        <paragraph id="idCB147BAB973E4496B7A6B1D3FAC1E42F">
          <enum>(4)</enum>
          <text>Generic drugs
			 cost substantially less than brand name drugs, with discounts off the brand
			 price sometimes exceeding 90 percent.</text>
				</paragraph>
        <paragraph id="idBCC57BA09EDA42A5B6C59A3A79141082">
          <enum>(5)</enum>
          <text>Federal dollars
			 currently account for an estimated 35 percent of the $263,000,000,000 spent on
			 prescription drugs, and this share is expected to rise to 42 percent by
			 2021.</text>
				</paragraph>
        <paragraph id="idEDEA23237CD74F3F946AF0EE3CF645A4">
          <enum>(6)</enum>
          <subparagraph commented="no" display-inline="yes-display-inline" id="id452D755DAB764402BCB2A908EEA35DD9">
            <enum>(A)</enum>
            <text>In recent years, the
			 intent of the 1984 Act has been subverted by certain settlement agreements
			 between brand companies and their potential generic competitors that make
			 <quote>reverse payments</quote> which are payments by the brand company to the
			 generic company.</text>
					</subparagraph>
          <subparagraph id="idCB09AA1594544BB29E1DC1576C3306EF" indent="up1">
            <enum>(B)</enum>
            <text>These settlement agreements have
			 unduly delayed the marketing of low-cost generic drugs contrary to free
			 competition, the interests of consumers, and the principles underlying
			 antitrust law.</text>
					</subparagraph>
          <subparagraph id="id13A8CB6F77D042259E34FD22EB4C692F" indent="up1">
            <enum>(C)</enum>
            <text>Because of the price disparity between
			 brand name and generic drugs, such agreements are more profitable for both the
			 brand and generic manufacturers than competition, and will become increasingly
			 common unless prohibited.</text>
					</subparagraph>
          <subparagraph id="id7FCBE969BB824E40BE3777DBD6DF0E4D" indent="up1">
            <enum>(D)</enum>
            <text>These agreements result in consumers
			 losing the benefits that the 1984 Act was intended to provide.</text>
					</subparagraph>
        </paragraph>
      </subsection>
      <subsection id="id747DD43FFF9B4A30966D1F063E7A3529">
        <enum>(b)</enum>
        <header>Purposes</header>
        <text>The
			 purposes of this Act are—</text>
				<paragraph id="id1B96D00562854784B1B3C9D760EEF96A">
          <enum>(1)</enum>
          <text>to enhance
			 competition in the pharmaceutical market by stopping anticompetitive agreements
			 between brand name and generic drug manufacturers that limit, delay, or
			 otherwise prevent competition from generic drugs; and</text>
				</paragraph>
        <paragraph id="id43318893879C4C7DA353C9739942D377">
          <enum>(2)</enum>
          <text>to support the
			 purpose and intent of antitrust law by prohibiting anticompetitive practices in
			 the pharmaceutical industry that harm consumers.</text>
				</paragraph>
      </subsection>
    </section>
    <section id="idB4948234563249969FAC1E282B914B90">
      <enum>3.</enum>
      <header>Unlawful
			 compensation for delay</header>
      <text display-inline="no-display-inline">The
			 <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Trade Commission Act">Federal Trade Commission Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/15/44/etseq">15 U.S.C. 44 et seq.</cato:entity-ref>)</cato:entity> is amended by—</text>
			<paragraph id="idD815DD162AA946C6B96988D670FE76F1">
        <enum>(1)</enum>
        <text>redesignating
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28">section 28</cato:entity-ref> as <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:29" proposed="true">section 29</cato:entity-ref>; and</text>
			</paragraph>
      <paragraph id="id2BBD926123F740B4B8C9ADF8127910F9">
        <enum>(2)</enum>
        <text>inserting before
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:29" proposed="true">section 29</cato:entity-ref>, as redesignated, the following:</text>
				<quoted-block display-inline="no-display-inline" id="id0174E948CF4741B098D1886E9118EE96" style="OLC">
					<section id="id9E27E4CD51C4430B906F95E4CFE64E79">
            <enum>28.</enum>
            <header>Preserving
				access to affordable generics</header>
						<subsection id="id1667386B3E624AC68C63EA2C6A7371C5">
              <enum>(a)</enum>
              <header>In
				general</header>
							<paragraph id="id63436B153AD14846B1A8D4E41A2D5F97">
                <enum>(1)</enum>
                <header>Enforcement
				proceeding</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Federal Trade Commission</cato:entity-ref> may initiate a proceeding
				to enforce the provisions of this section against the parties to any agreement
				resolving or settling, on a final or interim basis, a patent infringement
				claim, in connection with the sale of a drug product.</text>
							</paragraph>
              <paragraph id="id1E285B8FCB804B2C9C643CC1F571F63D">
                <enum>(2)</enum>
                <header>Presumption</header>
								<subparagraph id="id32221487CDDA4860A29E6C9D880C612F">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28/ss:a/p:1/sp:A" proposed="true">subparagraph (B)</cato:entity-ref>, in such a proceeding, an
				agreement shall be presumed to have anticompetitive effects and be unlawful
				if—</text>
									<clause id="idA9199D1F5ED24DB5A8C8A3E5671171F8">
                    <enum>(i)</enum>
                    <text>an ANDA filer
				receives anything of value; and</text>
									</clause>
                  <clause id="id15D0A68806C2453388D43A66E42DABC3">
                    <enum>(ii)</enum>
                    <text>the ANDA filer
				agrees to limit or forego research, development, manufacturing, marketing, or
				sales of the ANDA product for any period of time.</text>
									</clause>
                </subparagraph>
                <subparagraph id="idBA44F11F30B8483FAA75E3BA17E1B2D0">
                  <enum>(B)</enum>
                  <header>Exception</header>
                  <text>The
				presumption in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28/ss:a/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall not apply if the parties to such
				agreement demonstrate by clear and convincing evidence that the procompetitive
				benefits of the agreement outweigh the anticompetitive effects of the
				agreement.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="id615D4D72DF82411882E92CDAC50B6A85">
              <enum>(b)</enum>
              <header>Competitive
				factors</header>
              <text>In determining whether the settling parties have met
				their burden under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28/ss:a/p:2/sp:B" proposed="true">subsection (a)(2)(B)</cato:entity-ref>, the fact finder shall consider—</text>
							<paragraph id="id94CA010F8DA3402A9BD487B35308C129">
                <enum>(1)</enum>
                <text>the length of
				time remaining until the end of the life of the relevant patent, compared with
				the agreed upon entry date for the ANDA product;</text>
							</paragraph>
              <paragraph id="id5B11B8CE6B504CDC8788750A556FCD90">
                <enum>(2)</enum>
                <text>the value to
				consumers of the competition from the ANDA product allowed under the
				agreement;</text>
							</paragraph>
              <paragraph id="id2719A0FAEB46469893444FF970011CFF">
                <enum>(3)</enum>
                <text>the form and
				amount of consideration received by the ANDA filer in the agreement resolving
				or settling the patent infringement claim;</text>
							</paragraph>
              <paragraph id="id290EEBAAC98C4B7AA3761C0A57E6275C">
                <enum>(4)</enum>
                <text>the revenue the
				ANDA filer would have received by winning the patent litigation;</text>
							</paragraph>
              <paragraph id="id79FB09A3CE9F40649F4AD3515A89A5CA">
                <enum>(5)</enum>
                <text>the reduction in
				the NDA holder's revenues if it had lost the patent litigation;</text>
							</paragraph>
              <paragraph id="id307204363EAD4BD6AAAC869C76298FBB">
                <enum>(6)</enum>
                <text>the time period
				between the date of the agreement conveying value to the ANDA filer and the
				date of the settlement of the patent infringement claim; and</text>
							</paragraph>
              <paragraph id="idB5F40BB671E44170B91FF1A4489AE971">
                <enum>(7)</enum>
                <text>any other factor
				that the fact finder, in its discretion, deems relevant to its determination of
				competitive effects under this subsection.</text>
							</paragraph>
            </subsection>
            <subsection id="id2BA71E1AF5C54D7288E5650FA4E5A8F1">
              <enum>(c)</enum>
              <header>Limitations</header>
              <text>In
				determining whether the settling parties have met their burden under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28/ss:a/p:2/sp:B" proposed="true">subsection
				(a)(2)(B)</cato:entity-ref>, the fact finder shall not presume—</text>
							<paragraph id="id8D14AB9179334CEFBF7A1DAA741CA22D">
                <enum>(1)</enum>
                <text>that entry would
				not have occurred until the expiration of the relevant patent or statutory
				exclusivity; or</text>
							</paragraph>
              <paragraph id="id02A1905E17D24165A5CBE95F1E257E8E">
                <enum>(2)</enum>
                <text>that the
				agreement's provision for entry of the ANDA product prior to the expiration of
				the relevant patent or statutory exclusivity means that the agreement is
				pro-competitive, although such evidence may be relevant to the fact finder's
				determination under this section.</text>
							</paragraph>
            </subsection>
            <subsection id="idFB8D3387521043A398B7C336A6B02F7F">
              <enum>(d)</enum>
              <header>Exclusions</header>
              <text>Nothing
				in this section shall prohibit a resolution or settlement of a patent
				infringement claim in which the consideration granted by the NDA holder to the
				ANDA filer as part of the resolution or settlement includes only one or more of
				the following:</text>
							<paragraph id="idC4233AE997424716A592E8D86F1D51E9">
                <enum>(1)</enum>
                <text>The right to
				market the ANDA product in the United States prior to the expiration of—</text>
								<subparagraph id="id253FF1F071564DA7B90DF26DDE6F0490">
                  <enum>(A)</enum>
                  <text>any patent that
				is the basis for the patent infringement claim; or</text>
								</subparagraph>
                <subparagraph id="idAD30D6A58D7E4AE9969C528B0D5A72F8">
                  <enum>(B)</enum>
                  <text>any patent right
				or other statutory exclusivity that would prevent the marketing of such
				drug.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id69F79E95896549DA8CCD9C08EB155F2E">
                <enum>(2)</enum>
                <text>A payment for
				reasonable litigation expenses not to exceed $7,500,000.</text>
							</paragraph>
              <paragraph id="idB328783C939A4DA18FB13E29F4BF3174">
                <enum>(3)</enum>
                <text>A covenant not to
				sue on any claim that the ANDA product infringes a United States patent.</text>
							</paragraph>
            </subsection>
            <subsection id="ID9cb476ba491047adafcba4fc19ac64ef">
              <enum>(e)</enum>
              <header>Regulations and
				enforcement</header>
							<paragraph id="IDfbba9370d2eb407fa527883dda5105a3">
                <enum>(1)</enum>
                <header>Regulations</header>
                <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Federal Trade Commission</cato:entity-ref> may issue, in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/553">section 553 of title 5,
				United States Code</cato:entity-ref>, regulations implementing and interpreting this section.
				These regulations may exempt certain types of agreements described in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28/ss:a">subsection (a)</cato:entity-ref> if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref> determines such agreements will further market
				competition and benefit consumers. Judicial review of any such regulation shall
				be in the United States District Court for the District of Columbia pursuant to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/706">section 706 of title 5, United States Code</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="ID1a51445221234918b7dabd4e3f4d5813">
                <enum>(2)</enum>
                <header>Enforcement</header>
                <text>A
				violation of this section shall be treated as a violation of section 5.</text>
							</paragraph>
              <paragraph id="IDc6285493752f49bca374fc1db32af1f4">
                <enum>(3)</enum>
                <header>Judicial
				review</header>
                <text>Any person, partnership or corporation that is subject to
				a final order of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref>, issued in an administrative adjudicative
				proceeding under the authority of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28/ss:a/p:1" proposed="true">subsection (a)(1)</cato:entity-ref>, may, within 30 days of the
				issuance of such order, petition for review of such order in the United States
				Court of Appeals for the District of Columbia Circuit or the United States
				Court of Appeals for the circuit in which the ultimate parent entity, as
				defined at 16 CFR 801.1(a)(3), of the NDA holder is incorporated as of the date
				that the NDA is filed with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Secretary of the Food and Drug Administration</cato:entity-ref>,
				or the United States Court of Appeals for the circuit in which the ultimate
				parent entity of the ANDA filer is incorporated as of the date that the ANDA is
				filed with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Secretary of the Food and Drug Administration</cato:entity-ref>. In such a review
				proceeding, the findings of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref> as to the facts, if supported by
				evidence, shall be conclusive.</text>
							</paragraph>
            </subsection>
            <subsection id="IDa94a161bea14469e9672f06f1a17598a">
              <enum>(f)</enum>
              <header>Antitrust
				laws</header>
              <text>Nothing in this section shall be construed to modify, impair
				or supersede the applicability of the antitrust laws as defined in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                  <cato:entity-ref entity-type="act" value="Clayton Act/s:1/ss:a">subsection
				(a) of the 1st section of the Clayton Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/15/12/a">15 U.S.C. 12(a)</cato:entity-ref>)</cato:entity> and of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Clayton Act/s:5">section 5 of
				this Act</cato:entity-ref> to the extent that section 5 applies to unfair methods of competition.
				Nothing in this section shall modify, impair, limit or supersede the right of
				an ANDA filer to assert claims or counterclaims against any person, under the
				antitrust laws or other laws relating to unfair competition.</text>
						</subsection>
            <subsection id="ID283df0e6ecb14258818f3cddcd948d31">
              <enum>(g)</enum>
              <header>Penalties</header>
							<paragraph id="ID48d126dde11f41bea37b8c26ab42cdb5">
                <enum>(1)</enum>
                <header>Forfeiture</header>
                <text>Each
				person, partnership or corporation that violates or assists in the violation of
				this section shall forfeit and pay to the United States a civil penalty
				sufficient to deter violations of this section, but in no event greater than 3
				times the value received by the party that is reasonably attributable to a
				violation of this section. If no such value has been received by the NDA
				holder, the penalty to the NDA holder shall be sufficient to deter violations,
				but in no event greater than 3 times the value given to the ANDA filer
				reasonably attributable to the violation of this section. Such penalty shall
				accrue to the United States and may be recovered in a civil action brought by
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Federal Trade Commission</cato:entity-ref>, in its own name by any of its attorneys
				designated by it for such purpose, in a district court of the United States
				against any person, partnership or corporation that violates this section. In
				such actions, the United States district courts are empowered to grant
				mandatory injunctions and such other and further equitable relief as they deem
				appropriate.</text>
							</paragraph>
              <paragraph id="ID79513dc7ef114b7c9cc8b0b2fc9f91f8">
                <enum>(2)</enum>
                <header>Cease and
				desist</header>
								<subparagraph id="id1B31F24FB9DA4A61AD42948DA4E763C2">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref> has issued a cease and desist order
				with respect to a person, partnership or corporation in an administrative
				adjudicative proceeding under the authority of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28/ss:a/p:1" proposed="true">subsection (a)(1)</cato:entity-ref>, an action
				brought pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref> may be commenced against such person,
				partnership or corporation at any time before the expiration of one year after
				such order becomes final pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:5/ss:g" proposed="true">section 5(g)</cato:entity-ref>.</text>
								</subparagraph>
                <subparagraph id="idF6D9A2CD95EC4CE79D6DA73604A5C991">
                  <enum>(B)</enum>
                  <header>Exception</header>
                  <text>In
				an action under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28/ss:g/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, the findings of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref> as to the
				material facts in the administrative adjudicative proceeding with respect to
				such person's, partnership's or corporation's violation of this section shall
				be conclusive unless—</text>
									<clause id="id57762BD58A6346FCA77EFA50E8299B1A">
                    <enum>(i)</enum>
                    <text>the terms of such
				cease and desist order expressly provide that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref>'s findings shall
				not be conclusive; or</text>
									</clause>
                  <clause id="id0D2FF1ED8312499DA592E112CE4FA146">
                    <enum>(ii)</enum>
                    <text>the order became
				final by reason of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:5/ss:g/p:1">section 5(g)(1)</cato:entity-ref>, in which case such finding shall be
				conclusive if supported by evidence.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph id="ID5c8b854069124cce8fccb7a8d348cd07">
                <enum>(3)</enum>
                <header>Civil
				penalty</header>
                <text>In determining the amount of the civil penalty described
				in this section, the court shall take into account—</text>
								<subparagraph id="ID5f347dd5c79947ef98685e9a8bf2ac07">
                  <enum>(A)</enum>
                  <text>the nature,
				circumstances, extent, and gravity of the violation;</text>
								</subparagraph>
                <subparagraph id="IDb0cb627f8e9d48a59d1fabcc7bcbdf47">
                  <enum>(B)</enum>
                  <text>with respect to
				the violator, the degree of culpability, any history of violations, the ability
				to pay, any effect on the ability to continue doing business, profits earned by
				the NDA holder, compensation received by the ANDA filer, and the amount of
				commerce affected; and</text>
								</subparagraph>
                <subparagraph id="ID82310c320dbf44ef8058272ca8d0c78a">
                  <enum>(C)</enum>
                  <text>other matters
				that justice requires.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="ID0d6514da899b4b4e8b7179eb05089c8a">
                <enum>(4)</enum>
                <header>Remedies in
				addition</header>
                <text>Remedies provided in this subsection are in addition to,
				and not in lieu of, any other remedy provided by Federal law. Nothing in this
				paragraph shall be construed to affect any authority of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref> under
				any other provision of law.</text>
							</paragraph>
            </subsection>
            <subsection id="id45338E1757F643C799B30259F85E0E87">
              <enum>(h)</enum>
              <header>Definitions</header>
              <text display-inline="yes-display-inline">In this section:</text>
							<paragraph id="ID9a0af5253299480195f32b9ee9648c98">
                <enum>(1)</enum>
                <header>Agreement</header>
                <text>The
				term <term>agreement</term> means anything that would constitute an agreement
				under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                    <cato:entity-ref entity-type="act" value="Sherman Act/s:1">section 1 of the Sherman Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/15/1">15 U.S.C. 1</cato:entity-ref>)</cato:entity> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sherman Act/s:5">section 5 of this
				Act</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="ID6ea793b8002a4f0285f5a7055c9bd226">
                <enum>(2)</enum>
                <header>Agreement
				resolving or settling a patent infringement claim</header>
                <text>The term
				<term>agreement resolving or settling a patent infringement claim</term>
				includes any agreement that is entered into within 30 days of the resolution or
				the settlement of the claim, or any other agreement that is contingent upon,
				provides a contingent condition for, or is otherwise related to the resolution
				or settlement of the claim.</text>
							</paragraph>
              <paragraph id="ID56929fbb211a414ca7df0fbb683234e8">
                <enum>(3)</enum>
                <header>ANDA</header>
                <text>The
				term <term>ANDA</term> means an abbreviated new drug application, as defined
				under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                    <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">section 505(j) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/355/j">21 U.S.C.
				355(j)</cato:entity-ref>)</cato:entity>.</text>
							</paragraph>
              <paragraph id="IDc0463528122544fca03f40f990882fa8">
                <enum>(4)</enum>
                <header>ANDA
				filer</header>
                <text>The term <term>ANDA filer</term> means a party who has
				filed an ANDA with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="ID930cab20a44c40a3ba82c94467a12479">
                <enum>(5)</enum>
                <header>ANDA
				product</header>
                <text>The term <term>ANDA product</term> means the product to
				be manufactured under the ANDA that is the subject of the patent infringement
				claim.</text>
							</paragraph>
              <paragraph id="ID7ea5e89cb6bc44e8b397166c12d0b3f8">
                <enum>(6)</enum>
                <header>Drug
				product</header>
                <text>The term <term>drug product</term> means a finished
				dosage form (e.g., tablet, capsule, or solution) that contains a drug
				substance, generally, but not necessarily, in association with 1 or more other
				ingredients, as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/21,Code/314.3/b">section 314.3(b) of title 21, Code of Federal
				Regulations</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="ID4135ca39ff4742d88c6fbee3adc6109f">
                <enum>(7)</enum>
                <header>NDA</header>
                <text>The
				term <term>NDA</term> means a new drug application, as defined under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                    <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section
				505(b) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/355/b">21 U.S.C. 355(b)</cato:entity-ref>)</cato:entity>.</text>
							</paragraph>
              <paragraph id="ID9b609efd4f314ee09c9b4ab27baa9a1a">
                <enum>(8)</enum>
                <header>NDA
				holder</header>
                <text>The term <term>NDA holder</term> means—</text>
								<subparagraph id="IDa527cad2148b46038644216eeb49c659">
                  <enum>(A)</enum>
                  <text>the party that
				received <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">FDA</cato:entity-ref> approval to market a drug product pursuant to an NDA;</text>
								</subparagraph>
                <subparagraph id="ID019e5d65b2dd4351b12f57dcb90f7cdb">
                  <enum>(B)</enum>
                  <text>a party owning or
				controlling enforcement of the patent listed in the Approved Drug Products With
				Therapeutic Equivalence Evaluations (commonly known as the <quote>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">FDA</cato:entity-ref> Orange
				Book</quote>) in connection with the NDA; or</text>
								</subparagraph>
                <subparagraph id="ID78bbded87bf24bc38dc348801496b192">
                  <enum>(C)</enum>
                  <text>the predecessors,
				subsidiaries, divisions, groups, and affiliates controlled by, controlling, or
				under common control with any of the entities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28/ss:h/p:8/sp:A,B">subparagraphs (A)
				and (B)</cato:entity-ref> (such control to be presumed by direct or indirect share ownership of
				50 percent or greater), as well as the licensees, licensors, successors, and
				assigns of each of the entities.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="ID6dadb22b8d1b487980506fad0963be74">
                <enum>(9)</enum>
                <header>Patent
				infringement</header>
                <text>The term <term>patent infringement</term> means
				infringement of any patent or of any filed patent application, extension,
				reissue, renewal, division, continuation, continuation in part, reexamination,
				patent term restoration, patents of addition and extensions thereof.</text>
							</paragraph>
              <paragraph id="IDeff66b69e3b647bf8213e37fd877b00f">
                <enum>(10)</enum>
                <header>Patent
				infringement claim</header>
                <text>The term <term>patent infringement
				claim</term> means any allegation made to an ANDA filer, whether or not
				included in a complaint filed with a court of law, that its ANDA or ANDA
				product may infringe any patent held by, or exclusively licensed to, the NDA
				holder of the drug product.</text>
							</paragraph>
              <paragraph id="idFF88FBD4D5F240ACAE04FB1E92C634E9">
                <enum>(11)</enum>
                <header>Statutory
				exclusivity</header>
                <text>The term <term>statutory exclusivity</term> means
				those prohibitions on the approval of drug applications under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:E/cl:ii..iv">clauses (ii)
				through (iv) of section 505(c)(3)(E)</cato:entity-ref> (5- and 3-year data exclusivity), <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:527">section
				527</cato:entity-ref> (orphan drug exclusivity), or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505A">section 505A</cato:entity-ref> (pediatric exclusivity) of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic
				Act</cato:entity-ref>.</text>
							</paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</paragraph>
    </section>
    <section id="id88AA880E01E44214B36E20F8A664D64D">
      <enum>4.</enum>
      <header>Notice and
			 certification of agreements</header>
			<subsection id="ID948fbbd1203a4b7fb333ceea27b81e8f">
        <enum>(a)</enum>
        <header>Notice of all
			 agreements</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:c/p:2">Section 1112(c)(2) of the Medicare Prescription Drug,
			 Improvement, and Modernization Act of 2003</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/355/note">21 U.S.C. 355 note</cato:entity-ref>)</cato:entity> is amended
			 by—</text>
				<paragraph id="ID1e9e22c7333d4677b7ce883798907320">
          <enum>(1)</enum>
          <text>striking
			 <quote>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref> the</quote> and inserting the following: “the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref>—</text>
					<quoted-block display-inline="no-display-inline" id="id1574443D1642473587596FD6A608FEF2" style="OLC">
						<paragraph id="id8C3EE51A6F424F549A7A6020230FFFAD">
              <enum>(1)</enum>
              <text>the</text>
						</paragraph>
            <after-quoted-block>;</after-quoted-block>
          </quoted-block>
				</paragraph>
        <paragraph id="idE8C81546832544F9B220CE569383E074">
          <enum>(2)</enum>
          <text>striking the
			 period and inserting <quote>; and</quote>; and</text>
				</paragraph>
        <paragraph id="ID21dd65a16c3043f9978372346cf0bbb1">
          <enum>(3)</enum>
          <text>inserting at the
			 end the following:</text>
					<quoted-block display-inline="no-display-inline" id="id67D3937098544D308A6DB8A20AB1CF1C" style="OLC">
						<paragraph id="id0CBAD188A10E4959B221CE5D73D99A0E">
              <enum>(2)</enum>
              <text>any other
				agreement the parties enter into within 30 days of entering into an agreement
				covered by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:a">subsection (a)</cato:entity-ref> or
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:b">(b)</cato:entity-ref>.</text>
						</paragraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
      <subsection id="ID9fa55d3f27934fad9c6978f1fe5500a4">
        <enum>(b)</enum>
        <header>Certification
			 of agreements</header>
        <text>
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112">Section 1112 of such Act</cato:entity-ref> is amended by adding at
			 the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="id1E8A6CB53CA3499A90558B1A3525681C" style="OLC">
					<subsection id="ID5428698343d140d8bdf04af8e6282a76">
            <enum>(d)</enum>
            <header>Certification</header>
            <text>The
				Chief Executive Officer or the company official responsible for negotiating any
				agreement required to be filed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:a">subsection (a)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:b">(b)</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:c">(c)</cato:entity-ref> shall execute
				and file with the Assistant Attorney General and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref> a certification
				as follows: <quote>I declare that the following is true, correct, and complete
				to the best of my knowledge: The materials filed with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Federal Trade
				Commission</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1500">Department of Justice</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/t:XI/st:B/s:1112">section 1112 of subtitle B of
				title XI of the Medicare Prescription Drug, Improvement, and Modernization Act
				of 2003</cato:entity-ref>, with respect to the agreement referenced in this certification: (1)
				represent the complete, final, and exclusive agreement between the parties; (2)
				include any ancillary agreements that are contingent upon, provide a contingent
				condition for, or are otherwise related to, the referenced agreement; and (3)
				include written descriptions of any oral agreements, representations,
				commitments, or promises between the parties that are responsive to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:a">subsection
				(a)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112">(b) of such section 1112</cato:entity-ref> and have not been reduced to
				writing.</quote>.</text>
					</subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
    </section>
    <section id="id40DCD250172743DC859054FD065456A2">
      <enum>5.</enum>
      <header>Forfeiture of
			 180-day exclusivity period</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug and Cosmetic Act/s:505/ss:j/p:5/sp:D/cl:i/scl:V">Section 505(j)(5)(D)(i)(V) of the Federal
			 Food, Drug and Cosmetic Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/355/j/5/D/i/V">21 U.S.C. 355(j)(5)(D)(i)(V)</cato:entity-ref>)</cato:entity> is amended by
			 inserting <quote>
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28">section 28 of the Federal Trade Commission Act</cato:entity-ref> or</quote>
			 after <quote>that the agreement has violated</quote>.</text>
		</section>
    <section id="idC9F9F7A1B7B843BD9B566BBFDBD03077">
      <enum>6.</enum>
      <header>Commission
			 litigation authority</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Trade Commission Act/s:16/ss:a/p:2">Section
			 16(a)(2) of the Federal Trade Commission Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/15/56/a/2">15 U.S.C. 56(a)(2)</cato:entity-ref>)</cato:entity> is
			 amended—</text>
			<paragraph id="id2E28EBA7C1974E82921B96596A8F23A2">
        <enum>(1)</enum>
        <text display-inline="yes-display-inline">in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:16/ss:a/p:2/sp:D">subparagraph (D</cato:entity-ref>), by striking
			 <quote>or</quote> after the semicolon;</text>
			</paragraph>
      <paragraph id="idB2911E6E4CDE4282B77565BCC589CAB5">
        <enum>(2)</enum>
        <text display-inline="yes-display-inline">in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:16/ss:a/p:2/sp:E">subparagraph (E)</cato:entity-ref>, by inserting
			 <quote>or</quote> after the semicolon; and</text>
			</paragraph>
      <paragraph id="id63D1E5C340104384BC9406B21C20138C">
        <enum>(3)</enum>
        <text display-inline="yes-display-inline">inserting after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:16/ss:a/p:2/sp:E">subparagraph (E)</cato:entity-ref> the
			 following:</text>
				<quoted-block display-inline="no-display-inline" id="id179682837D3F4AB0AB8D35F53125F2E5" style="OLC">
					<subparagraph id="id7902E2B4ACBC42E7B3DEF865EE351259">
            <enum>(F)</enum>
            <text>under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28">section
				28</cato:entity-ref>;</text>
					</subparagraph>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</paragraph>
    </section>
    <section id="id28AB8E1DB7E5420C9054280D5AC464DF">
      <enum>7.</enum>
      <header>Statute of
			 limitations</header>
      <text display-inline="no-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref>
			 shall commence any enforcement proceeding described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28">section 28 of the
			 Federal Trade Commission Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Preserve Access to Affordable Generics Act/s:3" proposed="true">section 3</cato:entity-ref>, except for an action
			 described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Trade Commission Act/s:28/ss:g/p:2">section 28(g)(2) of the Federal Trade Commission Act</cato:entity-ref>, not later
			 than 3 years after the date on which the parties to the agreement file the
			 Notice of Agreement as provided by <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:c/p:2">sections 1112(c)(2)</cato:entity-ref> and <cato:entity-ref entity-type="act" value="Medicare Prescription Drug Improvement and Modernization Act of 2003/s:1112/ss:d/p:2">(d) of the Medicare
			 Prescription Drug Improvement and Modernization Act of 2003</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/355/note">21 U.S.C. 355
			 note</cato:entity-ref>)</cato:entity>.</text>
		</section>
    <section id="idCED49D6C42BC495C8D577636AB338618">
      <enum>8.</enum>
      <header>Severability</header>
      <text display-inline="no-display-inline">If any provision of this Act, an amendment
			 made by this Act, or the application of such provision or amendment to any
			 person or circumstance is held to be unconstitutional, the remainder of this
			 Act, the amendments made by this Act, and the application of the provisions of
			 such Act or amendments to any person or circumstance shall not be affected
			 thereby.</text>
		</section>
  </legis-body>
</bill>
</doc>